-
1 Comment
Champions Oncology, Inc is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Champions Oncology, Inc's total revenue rose by 20.0% to $11M since the same quarter in the previous year.
Its net income has increased by 81.8% to $740K since the same quarter in the previous year.
Finally, its free cash flow fell by 1088.9% to $-1M since the same quarter in the previous year.
Based on the above factors, Champions Oncology, Inc gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | F |
CurrencyCode | EUR |
ISIN | US15870P3073 |
Market Cap | 97M |
---|---|
PE Ratio | 17.95 |
Target Price | 15.67 |
Beta | 0.46 |
Dividend Yield | None |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2I3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025